HFrEF 药物治疗更新:系统综述与网络荟萃分析
该研究更新了2022年网络荟萃分析,纳入截至2025年4月的89项RCT共103,754例HFrEF患者,比较不同药物方案的疗效。结果显示,ARNi+β受体阻滞剂+MRA+SGLT2i四联疗法较安慰剂显著降低全因死亡(HR 0.35-0.39),五联加维利西呱可能额外获益,但证据为探索性。
要点
- 四联疗法(ARNi/β/MRA/SGLT2i)较安慰剂降低全因死亡HR 0.39(95%CI 0.32-0.49)。
- 五联加维利西呱HR 0.35(95%CI 0.27-0.45),较四联额外约0.7生命年。
- 70岁患者四联疗法较无治疗增加5.3生命年(95%CI 2.8-7.7)。
核心结论
- 当前推荐的四联疗法(ARNi、β受体阻滞剂、MRA、SGLT2i)在HFrEF患者中具有显著降低死亡和发病的获益。
- 加用维利西呱可能较四联疗法额外提供约0.7年生存获益,但结果源于单项试验的次要终点,应视为探索性。
研究设计与样本
- 研究为系统综述与频率学派网络荟萃分析,检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials数据库至2025年4月。
- 纳入89项随机对照试验,共103,754例HFrEF患者,比较不同药物治疗方案。
- 主要结局为全因死亡,次要结局为心血管死亡及心血管死亡或心衰住院复合终点,绝对获益使用BIOSTAT-CHF和ASIAN-HF队列数据量化为生命年。
主要发现
- 与安慰剂相比,ARNi+β受体阻滞剂+MRA+SGLT2i+维利西呱五联疗法最有效降低全因死亡(HR 0.35;95%CI 0.27-0.45)。
- 四联疗法(ARNi+β受体阻滞剂+MRA+SGLT2i)次之(HR 0.39;95%CI 0.32-0.49)。
- 代表性70岁患者,四联疗法较无治疗增加5.3生命年(95%CI 2.8-7.7),五联疗法增加6.0生命年(95%CI 3.7-8.4)。
关键数值与推荐
- 全因死亡HR:五联疗法0.35(95%CI 0.27-0.45),四联疗法0.39(95%CI 0.32-0.49),均对比安慰剂。
- 70岁患者生命年增益:四联疗法5.3年(95%CI 2.8-7.7),五联疗法6.0年(95%CI 3.7-8.4),均对比无治疗。
临床怎么用
- 对于HFrEF患者,应优先采用当前指南推荐的四联基础治疗(ARNi、β受体阻滞剂、MRA、SGLT2i)以显著降低死亡风险。
- 在四联疗法基础上,可考虑加用维利西呱以可能进一步改善生存,但需与患者讨论证据的探索性性质。
局限性
- 维利西呱的五联疗法结果源于单项试验(VICTOR)的次要终点,应视为探索性。
- 绝对获益(生命年)基于BIOSTAT-CHF和ASIAN-HF队列数据外推,可能存在人群差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2022, a network meta-analysis showed that a combination of β-blockers, angiotensin receptor-neprilysin inhibitors (ARNi), mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i) was most effective in reducing all-cause mortality in heart failure with reduced ejection fraction (HFrEF). This study updates the treatment benefit by including additional large randomized controlled trials (RCTs) since 2022, including the VICTOR (Vericiguat Global Study in Participants with Chronic Heart Failure) trial. OBJECTIVES: The goal of this study was to evaluate and compare regimens of pharmacotherapy in patients with HFrEF. METHODS: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases were searched for RCTs in patients with HFrEF through April 2025. Using frequentist network meta-analysis, HRs for all-cause mortality (primary outcome), cardiovascular death, and the composite of cardiovascular death or heart failure hospitalization (secondary outcomes) were estimated. Absolute benefits were quantified as life-years gained by using BIOSTAT-CHF (Biology Study to Tailored Treatment in Chronic Heart Failure) and ASIAN-HF (Asian Sudden Cardiac Death in Heart Failure) cohort data. RESULTS: The analysis included 103,754 patients across 89 randomized controlled trials. Relative to placebo, quintuple therapy with ARNi, β-blockers, MRAs, SGLT2i, and vericiguat most effectively reduced all-cause mortality (HR: 0.35; 95% CI: 0.27-0.45), followed by quadruple therapy with ARNi, β-blockers, MRAs, and SGLT2i (HR: 0.39; 95% CI: 0.32-0.49). For a representative 70-year-old patient, quadruple therapy (ARNi/β-blockers/MRAs/SGLT2i) provided 5.3 additional life-years (95% CI: 2.8-7.7) vs no treatment, while quintuple therapy (ARNi/β-blockers/MRA/SGLT2i/vericiguat) provided 6.0 additional life-years (95% CI: 3.7-8.4). CONCLUSIONS: This analysis reinforces the substantial mortality and morbidity benefit associated with the currently recommended quadruple therapy regimen (ARNi, β-blockers, MRAs, and SGLT2i) in patients with HFrEF. The addition of vericiguat may provide an incremental survival gain of approximately 0.7 year beyond that achieved with quadruple therapy. However, these results should be regarded as exploratory, as they are derived from a secondary endpoint of a single trial.
引用
- van Essen, Ceelen, Ouwerkerk, et al. Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis. J Am Coll Cardiol. 2025. PMID: 40892608. doi:10.1016/j.jacc.2025.08.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。